Back to Browse Journals » Open Access Journal of Clinical Trials » Volume 3

The future of the pharmaceutical, biological and medical device industry

Authors Burgess LJ, Terblanche M

Published Date September 2011 Volume 2011:3 Pages 45—50

DOI http://dx.doi.org/10.2147/OAJCT.S22199

Published 7 September 2011

Lesley J Burgess, Marli Terblanche
TREAD Research/Cardiology Unit, Department of Internal Medicine, Tygerberg Hospital and University of Stellenbosch, Parow, South Africa

Abstract: Numerous factors contribute to the declining pharmaceutical industry on the one hand and the rapidly growing generic industry together with the growing importance of medical devices and biologicals on the other. It is clear that the pharmaceutical industry is going to undergo a change in the next decade in order to meet the current challenges facing it and ultimately sustain its profitability and growth. This paper aims to identify a number of fairly obvious trends that are likely to have a significant impact on the product development pipeline in the next decade. It is more than clear that the current production pipeline for pharmaceutical, biotechnology and medical device industries is no longer sustainable and that urgent interventions are required in order to maintain its current level of profitability.

Keywords: pharmaceutical industry, personalized medicine, trends, generics, biotechnology

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Examining the readability of patient-informed consent forms

Marli Terblanche, Lesley Burgess

Open Access Journal of Clinical Trials 2010, 2:157-162

Published Date: 19 October 2010

Readers of this article also read:

Topical difluprednate for the treatment of Harada’s disease

Onishi SM, Asahi MG, Chou C, Gallemore RP

Clinical Ophthalmology 2015, 9:157-167

Published Date: 21 January 2015

Optimal management of breast cancer in the elderly patient: current perspectives

Le Saux O, Ripamonti B, Bruyas A, Bonin O, Freyer G, Bonnefoy M, Falandry C

Clinical Interventions in Aging 2015, 10:157-174

Published Date: 6 January 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Can low brain-derived neurotrophic factor levels be a marker of the presence of depression in obese women?

Celik Guzel E, Bakkal E, Guzel S, Eroglu HE, Acar A, Kuçukyalcin V, Topcu B

Neuropsychiatric Disease and Treatment 2014, 10:2079-2086

Published Date: 5 November 2014

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

Fukuda M, Shibata S, Shibata N, Hagihara K, Yaguchi H, Osada H, Takahashi N, Kubo E, Sasaki H

Clinical Ophthalmology 2013, 7:515-520

Published Date: 12 March 2013

Update on neuromyelitis optica: natural history and management

Jindahra P, Plant GT

Eye and Brain 2012, 4:27-41

Published Date: 28 March 2012

The cognitive impact of anticholinergics: A clinical review

Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.

Clinical Interventions in Aging 2009, 4:225-233

Published Date: 13 May 2009

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia

Terry Golombick, Terry Diamond

Biologics: Targets and Therapy 2008, 2:161-163

Published Date: 26 March 2008